Business Wire

Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups

Share

Deeptech Labs, the accelerator and VC fund for post-Seed, pre-Series A deeptech companies will unveil its Spring cohort of 6 deeptech start-ups to an online audience of investors on 21st June. More than 120 VCs and Corporate Entities have previously attended its virtual demo days, demonstrating the significant and growing interest in the European deeptech sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005112/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups (Graphic: Business Wire)

Deeptech Labs is a Cambridge-based accelerator programme and VC fund, founded in 2020 by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge. The accelerator supports deeptech entrepreneurs as they move from prototype and proof of concept to scalable products and services, and connects them to Deeptech Labs’ extensive network of deeptech investors.

The Deeptech Labs accelerator programme and investment fund was founded to fill a significant gap in the European venture market and accelerate the growth of promising early-stage deeptech companies. Deeptech Labs supports its cohort companies through a specially-designed thirteen week accelerator programme, connecting founders with a global network of more than 50 world-leading deeptech entrepreneurs, technology experts and investors.

Watch Demo Day elevator pitches from the Spring ’22 cohort:

Anaphite (Bristol, UK) incorporates graphene into battery materials, to enable the creation of super-fast charge, long-range batteries - something that will have significant impact on the EV market.

  • Watch Anaphite’s 3-minute elevator pitch here

Toposens (Munich, Germany) is the world’s only 3D ultrasonic sensing technology for advanced collision avoidance. It uses echolocation and signal processing algorithms to make autonomous vehicles in the robotics and automotive industry smarter and safer.

  • Watch Toposens’ 3-minute elevator pitch here

SonicEdge (Shoham, Israel) has developed the world’s smallest speaker-in-chip that uses breakthrough ultrasound technology to completely transform the audio experience.

  • Watch SonicEdge’s 3-minute elevator pitch here

iKVA (Cambridge, UK) is an early-stage AI Knowledge Management company creating solutions for organisations to discover data and intelligently and proactively provide it to users when they need it, enabling better business insights.

  • Watch iKVA’s 3-minute elevator pitch here

Inovo Robotics (Guildford, UK) are democratising robotics with modular, no-code, low cost “cobots” that open up completely new opportunities for safe, flexible automation.

  • Watch Inovo Robotics’ 3-minute elevator pitch here

Nestwave (Paris, France) Nestwave provides advanced, IoT geolocation solutions to IoT modem and DSP vendors to significantly improve localization accuracy in critical indoor and dense urban environments while greatly reducing power consumption and solution footprint.

  • Watch Nestwave’s 3-minute elevator pitch here

Miles Kirby, CEO Deeptech Labs said, “Europe has a number of global advantages in deeptech – we have 50% of the world’s best universities and the highest number of highly cited research papers - but there’s a disparity when it comes to European investment in deeptech companies. European deeptech companies attract $33 billion compared to $144 billion in the US.

Thanks to our deeptech-specific accelerator programme, our cohort companies are stronger, more resilient and have highly focused go-to-market strategies and that’s why so many investors attend our Demo Days – and how we are helping to fix the European deeptech investment gap.”

  • Watch Miles’ 5 minute introduction to Deeptech Labs here .

Editors Notes

Deeptech Labs is an accelerator, VC fund, and the catalyst for deeptech success. Twice a year, its cohort of start-ups are embedded in a powerful network of successful entrepreneurs, expert practitioners, leading researchers, and deeptech organisations worldwide. Deeptech Labs is founded by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge - forefront institutions and individuals at the heart of the Cambridge and global technology ecosystems.

The company is headquartered in Cambridge, UK.

For more information, please visit dtl.vc

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alex Monov, ThoughtLDR
alex@thoughtldr.com
+44 7391553411

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release

Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release

Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release

Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye